Condition
Myelofibroses
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Completed1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07492355Phase 1CompletedPrimary
TP-3654 Food Effect Study
NCT03326310Phase 1Recruiting
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
NCT03386214Phase 1TerminatedPrimary
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
NCT03718143Phase 2TerminatedPrimary
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
Showing all 4 trials